Patient case: Jack, aged 65 years, was diagnosed with peripheral artery disease (PAD). His symptoms did not improve with conservative treatments such as exercise therapy. Several months ago, Jack underwent lower-extremity revascularization to relieve his severe symptoms of leg pain. Since then, he has been taking dual pathway inhibition (DPI) with rivaroxaban vascular dose 2.5 mg twice daily (bid) plus low-dose aspirin to reduce his risk of vascular events. The procedure was successful and has improved his symptoms, allowing him to complete simple tasks around the house again. Jack has tolerated DPI therapy well, with no major bleeding events or contraindications, and has not experienced any vascular events. At a follow-up visit, he asks his physician when he should stop DPI therapy.
